SEC Comment Letter 0000000000-24-002379 to Fulcrum Therapeutics, Inc. (FULC) (CIK 0001680581) (FULC)
Fulcrum Therapeutics, Inc. (FULC) (CIK 0001680581)
Date: March 1, 2024 · CIK: 0001680581 · Accession: 0000000000-24-002379
AI Filing Summary & Sentiment
File numbers found in text: 333-277419
Letter
United States securities and exchange commission logo March 1, 2024 Alex Sapir President and Chief Executive Officer Fulcrum Therapeutics, Inc. 26 Landsdowne Street Cambridge, Massachusetts 02139 Re:Fulcrum Therapeutics, Inc. Registration Statement on Form S-3 Filed February 27, 2024 File No. 333-277419 Dear Alex Sapir: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Cindy Polynice at 202-551-8707 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Marianne Sarrazin, Esq.
Show Raw Text
United States securities and exchange commission logo
March 1, 2024
Alex Sapir
President and Chief Executive Officer
Fulcrum Therapeutics, Inc.
26 Landsdowne Street
Cambridge, Massachusetts 02139
Re:Fulcrum Therapeutics, Inc.
Registration Statement on Form S-3
Filed February 27, 2024
File No. 333-277419
Dear Alex Sapir:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Cindy Polynice at 202-551-8707 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Marianne Sarrazin, Esq.